Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2267738

COc1cccc(NC(=O)Nc2cccc(CNc3c[nH]nc3C(N)=O)c2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.55
RPS6KB1 P23443 3/20 0.55
PDPK1 O15530 1/20 0.55
HIF1A Q16665 1/20 0.53
MAPT P10636 4/20 0.47
AURKB Q96GD4 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
PARP1 P09874 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MITF O75030 1/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2266106 0.95 AURKA (0.50) AURKARPS6KB1PDPK1HIF1AMAPT
SCHEMBL3821817 0.94 AURKA (0.60) AURKARPS6KB1PDPK1HIF1AMAPT
Trifluoroacetic Acid SCHEMBL2266500 0.94 HIF1A (0.52) AURKARPS6KB1PDPK1HIF1AAURKB
Trifluoroacetic Acid SCHEMBL2273445 0.92 MAPT (0.51) AURKARPS6KB1PDPK1HIF1AMAPT
Trifluoroacetic Acid SCHEMBL2269640 0.90 AURKA (0.58) AURKARPS6KB1PDPK1HIF1AMAPT
Trifluoroacetic Acid SCHEMBL2267555 0.90 PARP1 (0.47) AURKARPS6KB1PDPK1HIF1AMAPT
SCHEMBL3822413 0.90 AURKA (0.54) AURKARPS6KB1PDPK1HIF1AMAPT
Trifluoroacetic Acid SCHEMBL2266587 0.89 AURKA (0.54) AURKARPS6KB1PDPK1HIF1AAURKB
Trifluoroacetic Acid SCHEMBL2267257 0.89 AURKA (0.52) AURKARPS6KB1PDPK1MAPTAURKB
Trifluoroacetic Acid SCHEMBL2266806 0.88 HIF1A (0.53) AURKARPS6KB1PDPK1HIF1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989439-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI-AVENTIS (FR) 2011-08-02 US claimed
US-20090291984-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2009-11-26 US claimed
US-8420824-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI (FR) 2013-04-16 US disclosed
US-8410286-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI-AVENTIS (FR) 2013-04-02 US disclosed
US-20110237801-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2011-09-29 US disclosed
US-20110237641-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2011-09-29 US disclosed
US-7989439-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI-AVENTIS (FR) 2011-08-02 US disclosed
US-20090291984-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237801-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE ADORA3, ADORA2B, CYP4B1 AURKA 693/4885RPS6KB1 422/4885PDPK1 1869/4885
US-20090291984-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE CYP4B1, ADORA1, CYP1B1 AURKA 719/4885RPS6KB1 310/4885PDPK1 1673/4885
US-20110237641-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE ADORA3, ADORA2B, CYP4B1 AURKA 693/4885RPS6KB1 422/4885PDPK1 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.